Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
² Department of Infectious Diseases, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
³ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia. Electronic address: britt.christensen@mh.org.au.

Comment

Ralley E Prentice et al. Dig Liver Dis. 2020 Nov.

. 2020 Nov;52(11):1250-1251.

doi: 10.1016/j.dld.2020.08.035. Epub 2020 Aug 27.

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
² Department of Infectious Diseases, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
³ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia. Electronic address: britt.christensen@mh.org.au.

No abstract available

Comment in

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.
Zingone F, Buda A, Savarino E. Zingone F, et al. Dig Liver Dis. 2020 Nov;52(11):1252-1253. doi: 10.1016/j.dld.2020.09.020. Epub 2020 Oct 10. Dig Liver Dis. 2020. PMID: 33051162 Free PMC article. No abstract available.

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.
Zingone F, Buda A, Savarino EV. Zingone F, et al. Dig Liver Dis. 2020 Jun;52(6):604-605. doi: 10.1016/j.dld.2020.04.004. Epub 2020 Apr 10. Dig Liver Dis. 2020. PMID: 32360133 Free PMC article.

1. Zingone F, Buda A, Savarino EV. Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Dig Liver Dis. 2020;52(6):604–605. - PMC - PubMed
1. Rubin DT, Abreu MT, Rai V, Siegel CA. Management of patients with Crohn's disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159(1):6–13. e16. - PMC - PubMed
1. Brenner EJ, Ungaro RC, Gearry RB. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020 eprint. - PMC - PubMed
1. Simon D, Tascilar K, Krönke G. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11(1):3774. - PMC - PubMed
1. Bond K, Nicholson S, Lim SM. Evaluation of serological tests for SARS-CoV-2: implications for serology testing in a low-prevalence setting. J Infect Dis. 2020 - PMC - PubMed